University of Utah Research Foundation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Miami

Kent Lai

Manshu Tang

Li Liu

Min Shen

Matthew Brian Boxer

Martin J Walsh

Douglas S Auld

Cordelle D Tanega

Klass Jan Wierenga

Disclosed are inhibitors of human galactokinase of formula (I) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I). 

Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I). 

Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.

Galactokinase inhibitors

Growing community of inventors

Salt Lake City, UT, United States of America

Kent Lai